La cadena de opciones muestra datos clave de las opciones de acciones de SILO Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para SILO Pharma..

SILO Pharma (NASDAQ:SILO) Bolsa, Cadena de Opciones

SILO Pharma

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

New,York,,Usa,-,January,07,,2025:,E2open,Website,Displayed

ABEO

BLMZ

CMBM

DGLY

DGNX

ETWO

GORV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IMNN

IXHL

ONCY

PMAX

PRTA

SBET

SILO

VVPR

WORX

Consulta las acciones con mayores subidas y caídas en el premercado estadounidense de hoy, incluyendo tecnológicas, biotecnológicas y más.

Las acciones de E2open se disparan un 25%; aquí están 20 acciones que se mueven en el premercado

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

AZTR

GANX

Descubre las últimas transacciones de insiders en penny stocks como ALZN, GANX, AZTR y SILO. ¡Aprovecha esta información privilegiada ahora!

Compras de insiders de penny stocks: ALZN, GANX, AZTR, SILO

SILO Pharma Inc

Silo Wellness Inc

Offerings

AVXL

Anavex Life Sciences Corp Files For Common Stock Offering Of Up To $300M

<ul>
<li>Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY&#xAE; (crinecerfont) achieved clinically meaningful weight reductions</li>
<li>Substantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatment</li>
</ul>
SAN DIEGO, July 14, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4466816-1&amp;h=1279460685&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced the presentation of new data from the Phase 3 CAHtalyst&#x2122; Adult and Pediatric studies showing favorable trends in improvement of weight-related outcomes in patients with classic congenital adrenal hyperplasia who were treated with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4466816-1&amp;h=2365011260&amp;u=https%3A%2F%2Fwww.crenessity.com%2F&amp;a=CRENESSITY%C2%AE+(crinecerfont)">CRENESSITY&#xAE; (crinecerfont)</a>&nbsp;for up to one year. These data were presented at the Endocrine Society's Annual Meeting, ENDO 2025, that is taking place July 12-15 in San Francisco. &nbsp;
The Phase 3 CAHtalyst program was the largest-ever interventional clinical trial program in classic congenital adrenal hyperplasia (CAH) and included 103 pediatric (four to 17 years of age) patients and 182 adult (18 to 58 years of age) patients. Both the CAHtalyst Pediatric study and the CAHtalyst Adult study consisted of an initial six-month, double-blind, placebo-controlled (DBPC) period (28 weeks for the pediatric study and 24 weeks for the adult study) followed by a 24-week open-label (OL) period, during which all patients received CRENESSITY. During both the DBPC and OL periods, glucocorticoid (GC) doses were kept stable for the first four weeks and then decreased as tolerated toward more physiologic levels while maintaining or improving androstenedione (A4) relative to Day 1 baseline.
Adult and pediatric patients receiving CRENESSITY for up to one year saw improvements in key weight-related outcomes: &nbsp;
<ul>
<li>Adults taking CRENESSITY experienced greater reductions in body mass index (BMI) at Week 24 versus placebo, with further reductions from baseline observed through Month 12.</li>
<li>Pediatric patients taking CRENESSITY saw reductions in BMI standard deviation scores (SDS) at Week 28, while those taking placebo saw an increase. Reductions in the CRENESSITY group were maintained through Week 52.</li>
<li>Among adult and pediatric patients who were overweight or obese at baseline (~70% and ~60%, respectively):
<ul>
<li>A higher percentage of adults achieved a greater than 5% reduction in weight at Week 24 with&nbsp;CRENESSITY versus placebo.</li>
<li>A higher percentage of pediatric patients achieved at least a 0.2 reduction from baseline in&nbsp;BMI SDS at Week 28 with CRENESSITY versus placebo.</li>
<li>Importantly, the percentage of adult and pediatric patients achieving these thresholds increased through Week 52 for both patients on continuous&nbsp;CRENESSITY and those who switched to CRENESSITY from placebo.</li>
<li>In those with insulin resistance, mean homeostatic model assessment for insulin resistance (HOMA-IR) was elevated at baseline; greater reductions in HOMA-IR were observed with CRENESSITY than placebo in both adult and pediatric patients at the end of the DBPC periods, and substantial reductions from baseline were observed through one year of treatment.</li>
</ul>
</li>
</ul>

Biotech

General

NBIX

Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025

<ul>
<li>Mr. Rajiv Shukla, Chairman and CEO of Longevity, will serve as Executive Chairman, and Mr. George Chi, Founder and CEO of THPlasma, will be appointed as Co-Chairman and CEO post-Closing.</li>
</ul>

Management

Longevity Health Holdings, Inc. - Common Stock

XAGE

Longevity Health Holdings Announces Rajiv Shukla To Be Executive Chairman; George Chi Appointed As Co-Chairman And CEO, Post Closing

PUMP

ProPetro Appoints Caleb Weatherl As CFO

Horizon capped a three-week whirlwind with the introduction of <a href="https://www.benzinga.com/etfs">two new ETFs</a>, taking its total ETF lineup to nine since January. The newly launched funds, the Horizon Nasdaq 100 Defined Risk ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QGRD#NASDAQ">QGRD</a>) and the Horizon Digital Frontier ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YNOT#NASDAQ">YNOT</a>), are designed to combine growth potential with downside protection, further strengthening Horizon's goal-based investing philosophy.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/07/46402939/higher-yields-without-junk-bonds-reckoners-new-etf-offers-new-spin-on-clos">Higher Yields Without Junk Bonds: Reckoner&#8217;s New ETF Offers New Spin On CLOs</a>
<h2 class="wp-block-heading">Get To Know QGRD And YNOT</h2>
QGRD seeks exposure to the technology-rich Nasdaq-100 Index through the use of an options overlay strategy, which hedges against downside risk. It aims to provide both capital appreciation and capital preservation, a combination that may appeal to advisors navigating the skittish markets of today.
YNOT, however, is at the forefront of digital advancements. It primarily invests in the equities of firms in the digital and technology industries, with a focus on long-term capital appreciation from companies driving digital change.
<h2 class="wp-block-heading">Fast-Tracked Growth</h2>
Since its ETF debut in January with just two funds, Horizon has rapidly expanded to nine active ETFs, all crafted with a goals-based framework meant to support various investor objectives, from wealth accumulation to retirement readiness.
Horizon&#8217;s new launches demonstrate that the company isn&#8217;t merely following ETF trends, it&#8217;s trying to provide advisors with tactical solutions to construct bespoke, risk-managed portfolios.
Read next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/07/46398559/are-your-tesla-etfs-secretly-betting-on-elon-musks-ai-startup">Are Your Tesla ETFs Secretly Betting On Elon Musk&#8217;s AI Startup?</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

QGRD

YNOT

YNOT Invest In Tech? Horizon's New ETFs Balance Innovation And Risk

SANW

S&W Seed Company To Voluntary Delist From Nasdaq; Announces SEC Deregistration

Guidance

Range Resources Corp. Expects To Report A Total Gain On Derivatives Of $154.7M For The Three Months Ended June 30, 2025

Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>), a company focused on human longevity and healthy aging ("Longevity", the "Company", "we", "our", or "us"), today announced the execution of a definitive merger agreement (the "Merger") with True Health Inc., a leading player in the fast growing plasma collection industry under the THPlasma brand ("THPlasma"), to combine the companies in an all-stock transaction. Following the closing of the Merger (the "Closing"), the combined company is expected to continue to trade on Nasdaq under the symbol "XAGE."
Longevity today also announced the mutual termination of the 20/20 BioLabs transaction pursuant to the terms of the merger agreement.
The announced merger with THPlasma follows Longevity's acquisition of Carmell Therapeutics ("Carmell") in July 2023 and&nbsp;Elevai Skincare&nbsp;("Elevai") in January 2025. The Carmell technology platform is based on plasma-derived growth factors, whereas Elevai is based on exosomes derived from hUM stem cells.
Despite supplying over 60% of the world's plasma, the United States faces a shortfall in plasma and plasma-derived therapeutics - like immunoglobulins, clotting factors, and albumin. THPlasma is playing a critical role in addressing this shortfall with a rapidly growing footprint of plasma collection centers.

Longevity Health Executes Definitive Merger Agreement With True Health To Combine Companies In All-Stock Transaction; Longevity Announces Mutual Termination Of 20/20 Biolabs Transaction

Churchill Downs Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) (the "Company", "CDI", "we") announced today that it has signed definitive agreements to acquire a majority of the outstanding equity interests (the "Salem Transaction") of a Salem, New Hampshire joint venture ("Casino Salem") with the right to develop a charitable gaming, entertainment and dining destination featuring historical horse racing machines ("HRMs").
Casino Salem is located at The Mall at Rockingham Park, which is approximately 30 minutes from downtown Boston. Prominent local developers Joe Faro and Sal Lupoli will maintain ownership in Casino Salem, ensuring their experience remains central to the development and future success of this new venue.
The initial phase of Casino Salem opened on July 9th with approximately 100 HRMs and 13 live table games. Over the coming months, CDI will finalize plans and commence construction of the future phases of the project including a rebranding of the venue, an expansion of the gaming floor, and several food and beverage concepts.

CHDN

Churchill Downs To Acquire Majority Stake In Salem, NH Casino Project Featuring Historical Horse Racing Machines; No Financial Terms Disclosed

SNWV

Sanuwave Health Sees Prelim. Q2 Revenue $10.1M-$10.2M

Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) has outperformed the market over the past 15 years by 12.17% on an annualized basis producing an average annual return of 24.55%. Currently, Mastercard has a market capitalization of $502.23 billion. 
Buying $100 In MA: If an investor had bought $100 of MA stock 15 years ago, it would be worth $2,823.98 today based on a price of $553.02 for MA at the time of writing.
<h3>Mastercard's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752525014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Mastercard Stock In The Last 15 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/KHRNF">Khiron Life Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KHRNF#OTC">KHRNF</a>) shares closed up 900.00% at $1e-05</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 21.59% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 13.67% at $1.58</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 12.90% at $0.66</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed up 12.63% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 11.85% at $0.32</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 3.82% at $0.43</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 3.06% at $0.07</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 33.33% at $0.0005</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 18.27% at $5.14</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 15.18% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 14.29% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 11.05% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 8.71% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 8.14% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 6.83% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed down 6.25% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 5.28% at $0.62</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 5.02% at $0.31</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 4.58% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 4.46% at $1.49</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 4.23% at $0.19</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 4.21% at $3.05</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 3.66% at $0.50</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 3.50% at $8.63</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 3.01% at $0.04</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Movers

BBRRF

BLGVF

BLOZF

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CRLBF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CWBHF

CXXIF

FFNTF

GNLN

KAYS

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

LMLLF

MRMD

NWVCF

RMHB

RSSFF

SNDL

SOLCF

TGIFF

TLRY

XXII

ZDPY

Cannabis Stock Movers For July 14, 2025

Tabby Toney didn't set out to have a career in tech. She followed a friend into the industry, doing manual testing of software, with little prior experience and no clear idea of where she wanted the field to take her.&nbsp;
It didn't take long, though, for the Oklahoman to fall in love with the industry. "I loved tech because of the intellectual stimulation it provided. I enjoyed the creative problem-solving and critical thinking required to make things happen," she told <a href="https://www.businessinsider.com/laid-off-from-tech-job-now-pursuing-career-in-welding-2025-7">Business Insider</a>.
So she set to learning everything she could, taking virtual classes and studying in her downtime. Eventually, she became a software engineer in her own right.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
Things were going swimmingly until May, when Toney was laid off. It was something she'd seen coming, largely because of the direction the industry was heading with AI. Having financially prepared for the change, she initially intended to take a month off of work entirely in order to reset and decide what her next steps would be.
"But I don&#8217;t sit still very well," she said. "So I decided to take up welding."
"I didn&#8217;t want to start over again, but I also didn&#8217;t want to be bored," she explained to Business Insider. "I needed something to keep me engaged and feeling like I was contributing, but my tech job didn&#8217;t do that anymore."
Much like software engineering, Toney's choice to pursue welding wasn't super intentional. "I took welding in high school, and I remember running around as a kid in my grandpa&#8217;s garage, where he and my dad did it a bunch," she said.
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
Once she got started, Toney found that the work mirrored some of her favorite things about software engineering. "I enjoy [welding] because it&#8217;s creative. However, metallurgy also involves knowing what to use and how to do it in certain situations, so there&#8217;s still a thinking aspect to it. I also like working with my hands," she said.&nbsp;
Despite her love for welding, her ultimate transition out of tech wasn't an easy decision. "Tech has always excited me," Toney said, before noting that the industry was wrestling with some real issues. "I think the problem is the industry's reliance on AI when it&#8217;s not ready yet. Also, a lot of decisions are being made by non-tech people who don&#8217;t fully understand how it affects the people who are writing the tech."
"With how the industry is now, I&#8217;m pretty happy with my decision. I thought I would be a nervous wreck forever, but I was ready. I feel so relieved now that I have left tech and have a new plan," she said.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li>This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

'I Feel So Relieved Now That I Have Left Tech': Why The Rise Of AI Led This Woman To Leave The Industry

UAVS

NYSE American Accepts AgEagle Aerial Systems Plan To Regain Compliance

MYR Group Inc. (&quot;MYR Group&quot;) (NASDAQ:<a href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United States and Canada, announced that an MYR Group subsidiary has executed a five-year Design-Build Electric Distribution Master Service Agreement (MSA) with Xcel Energy Inc. (Xcel Energy). The MSA includes turnkey, design-build distribution services including, permitting, right of way, public outreach, design and construction in Xcel Energy&#39;s service territories across multiple states. The contract is effective through 2029, and it is anticipated that work under this MSA will be in excess of $500 million over the five-year period.

MYRG

MYR Group Subsidiary Executes $500M, 5-Yr Design-Build Electric Distribution Master Service Agreement With Xcel Energy

Trading Halt: Halted at 4:25:00 p.m. ET - Trading Halt: Halt News Pending

WIIM

BloomZ shares are trading higher after the company announced it is partnering with HYPERCOMMUNITY to deliver an AI-driven VTuber platform

La-Z-Boy Expects Q1 Sales And Operating Margin To Be Around Lower End Of Previously Issued Guidance Ranges

For shareholders who appreciate the long-term growth of <a href="https://www.benzinga.com/topic/s-p-500-index" target="_blank" rel="noopener">the S&amp;P 500</a> but prefer to avoid the tax implications associated with dividends, Roundhill Investments has recently introduced a new option.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/07/46402939/higher-yields-without-junk-bonds-reckoners-new-etf-offers-new-spin-on-clos">Higher Yields Without Junk Bonds: Reckoner&#8217;s New ETF Offers New Spin On CLOs</a>
The Roundhill S&amp;P 500 No Dividend Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/XDIV#BATS">XDIV</a>), which began trading on July 10, aims to achieve something no <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener">ETF</a> has ever attempted before: providing exposure to the entire S&amp;P 500 Index while actively reducing dividend payouts.
The pitch is simple. Most investors, especially those in tax accounts, view dividends as less &#8220;free money&#8221; and more as a yearly tax hassle. XDIV is designed for tax-conscious investors, offering the potential for long-term capital appreciation with distributions maintained at a level as close to zero as possible.
Roundhill CEO Dave Mazza noted that the dividend in itself is not bad. But for some investors, skipping them can equate to better after-tax results.
<h2 class="wp-block-heading">A Niche For The Tax-Savvy</h2>
In contrast to common dividend-averse strategies that avoid high-yielding stocks, XDIV forges a new path: it maintains full S&amp;P 500 exposure while still attempting to avoid distributions. Although the ETF can&#8217;t guarantee zero distributions, its approach is designed to minimize them significantly, without compromising diversification.
It&#8217;s a niche concept, but one that could attract high-net-worth investors or capital gains managers with surgical-like precision. It might even appeal to younger investors seeking to compound returns without paying taxes each year.
It&#8217;s also unusually inexpensive. With a net expense ratio of 0.0849%, XDIV is among the cheapest S&amp;P 500-tracking ETFs available.
Tax-efficiency is hardly a brand-new fix in ETF land, but XDIV raises it to an art form. Whether the public bites will hinge on whether they believe dividend avoidance is worthwhile, or whether they prefer to reinvest the payments themselves.
Nevertheless, in an ETF space where &#8220;thematic&#8221; tends to translate to &#8220;gimmicky,&#8221; Roundhill&#8217;s no-dividend spin comes off as refreshingly earthy. It&#8217;s not trend-hunting. It&#8217;s tax efficiency.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46401147/silver-etfs-just-crashed-golds-party-and-took-the-cake">Silver ETFs Just Crashed Gold&#8217;s Party— And Took The Cake</a></li>
</ul>
Photo: Shutterstock

XDIV

S&P 500 Reinvented: Dividends Out, Growth In With XDIV ETF

FB Financial shares are trading lower after the company reported a Q2 revenue miss.

Press Releases

Silo Pharma Announces Pricing of $2 Million Public Offering

Silo Pharma Announces Closing of $2 Million Public Offering

Health Care

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Legal

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

HOTH

Aditxt

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Azitra

Bone Biologics

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Soligenix

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Laidlaw & Co.

Screenshot 2024-05-21 at 6.46.56 PM

ATAI

FTRP

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies

Comments

SILO Pharma

SILO Pharma (SILO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL